Natus Medical Inc. (NASDAQ:BABY)’s share price fell 2.4% during mid-day trading on Wednesday . The company traded as low as $38.99 and last traded at $39.33, with a volume of 475,506 shares trading hands. The stock had previously closed at $40.30.

A number of research firms have issued reports on BABY. Roth Capital restated a “buy” rating on shares of Natus Medical in a research report on Thursday, April 21st. Zacks Investment Research upgraded shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a research report on Thursday, July 7th. Finally, Raymond James Financial Inc. cut shares of Natus Medical from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 5th.

The company has a market cap of $1.27 billion and a P/E ratio of 33.69. The stock’s 50-day moving average is $37.35 and its 200 day moving average is $35.75.

Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, July 20th. The company reported $0.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.03. The company had revenue of $96 million for the quarter, compared to analysts’ expectations of $92.71 million. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 earnings per share. On average, equities analysts forecast that Natus Medical Inc. will post $1.67 EPS for the current fiscal year.

In other Natus Medical news, Director Robert A. Gunst sold 5,000 shares of the stock in a transaction on Tuesday, April 26th. The shares were sold at an average price of $34.61, for a total transaction of $173,050.00. Following the completion of the transaction, the director now owns 55,000 shares in the company, valued at $1,903,550. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

A number of institutional investors have added to or reduced their stakes in BABY. Sawtooth Asset Management Inc. raised its position in Natus Medical by 6,178.3% in the fourth quarter. Sawtooth Asset Management Inc. now owns 25,490 shares of the company’s stock valued at $1,225,000 after buying an additional 25,084 shares during the period. Rhumbline Advisers raised its position in Natus Medical by 10.8% in the fourth quarter. Rhumbline Advisers now owns 42,850 shares of the company’s stock valued at $2,059,000 after buying an additional 4,165 shares during the period. Sei Investments Co. raised its position in Natus Medical by 1,021.6% in the fourth quarter. Sei Investments Co. now owns 56,452 shares of the company’s stock valued at $2,712,000 after buying an additional 51,419 shares during the period. PNC Financial Services Group Inc. raised its position in Natus Medical by 12.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 63,516 shares of the company’s stock valued at $3,053,000 after buying an additional 7,125 shares during the period. Finally, Pear Tree Advisors Inc. acquired a new position in Natus Medical during the fourth quarter valued at approximately $3,182,000.

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.